|
Drug Therapy for Alcohol Detoxification Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Drug Therapy for Alcohol Detoxification conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Drug Therapy for Alcohol Detoxification Clinical research trials and Drug Therapy for Alcohol Detoxification medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Drug Therapy for Alcohol Detoxification. Drug Therapy for Alcohol Detoxification Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Drug Therapy for Alcohol Detoxification clinical trial. Subjects typically recieve the finest healthcare available for their Drug Therapy for Alcohol Detoxification condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Drug Therapy for Alcohol Detoxification  Drug Therapy for Alcohol Detoxification
Drug Therapy for Alcohol Detoxification
For Condition: Alcoholism
Status: Completed
Sponsor(s): National Institute on Alcohol Abuse and Alcoholism (NIAAA) ,
Synopsis: This project will provide relevant clinical information for primary care practitioners treating alcohol withdrawal syndrome in outpatient settings. This double-blind, placebo- controlled clinical trial will compare the effectiveness of lorazepam (Ativan) and carbamazepine (Tegretol) in alcoholics who meet the criteria for a diagnosis of uncomplicated alcohol withdrawal syndrome. Participants are randomized to five days of treatment with a 1-week posttreatment followup.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 21 Years/70 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Meets criteria for alcohol dependence and uncomplicated alcohol withdrawal syndrome. - Ability to provide informed consent, complete self-rating questionnaires, and respond to structured clinician-rated instruments. - Must live within 50 miles or one hour of the study site and have reliable transportation to the site. - Must have a significant other who will provide a collateral report, attend outpatient visits, and be available by telephone. - Subjects must be medically stable. - Must have a clinical withdrawal assessment prior to study. Exclusion Criteria: - Meets criteria for any other substance dependence syndrome other than alcohol dependence or marijuana abuse. - Use of other illicit psychoactive substances (except marijuana) in the last 7 days. - Use of pharmaceutical agents within the last 14 days that are known to lower the seizure threshold, augment or decrease the alcohol withdrawal syndrome. - History of status epilepticus or two or more seizures occurring within 24- hour period during a previous alcohol withdrawal or other forms of epilepsy. - Current major depressive illness, dementia, suicidal or homicidal ideation, or past or present schizophrenia. - Acute medical instability as characterized by hepatic encephalopathy, past or present severe liver failure. - Diabetes requiring insulin, or severe renal disease. - Pregnant females. - High blood pressure. - Individuals with vomiting who cannot take oral medications at beginning of study or whose vomiting can be controlled only with antiemetic medication. - High white blood count, or liver function test that is 3 times higher than normal. - Known hypersensitivity or previous adverse reaction to carbamazepine, lorazepam, or other benzodiazepines. - Any relevant ECG abnormality which might require hospitalization or greatly interfere with safety during outpatient withdrawal. - History of severe gastrointestinal (GI) disease which might render absorption of the medication difficult or produce medical instability of the patient during detoxification which would include active peptic ulcer disease, ulcerative colitis, regional ileitis, or evidence by history or physical examination of GI bleeding. - Familial tremor or other neurological condition, determined by history, known to produce tremor. - Unable to provide a written informed consent.
Total Enrollment:
Location and Contact Information:
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina
Charleston, South Carolina, 29425
United States
Additional Information:
Study ID Numbers: NIAAAMAL10761;
Study Start Date:
Record last reviewed: August 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000441
Other Alcoholism Studies:
1. Naltrexone for Relapse Prevention
2. Treatment of Adolescents with Comorbid Alcohol Use and Attention Deficit Hyperactivity Disorder (bupropion)
3. Trazodone for Sleep Disturbance in Early Alcohol Recovery
4. Naltrexone Treatment for Alcoholic Women
5. Use of Naltrexone in a Clinical Setting
Related Studies:
Other Alcoholism Clinical Trials
Other South Carolina Clinical Trials
Other Charleston Clinical Trials
Drug Therapy for Alcohol Detoxification
|
|
|
|
|
|
|
|
